3 Global Growth Companies With High Insider Ownership
In recent weeks, global markets have experienced a mix of optimism and caution, with easing inflation concerns and favorable AI-related earnings juxtaposed against rising oil prices and geopolitical uncertainties. Amid this backdrop, investors are increasingly looking for growth companies where high insider ownership aligns management's interests with shareholders'—a key factor in navigating today's complex market environment.
Top 10 Growth Companies With High Insider Ownership Globally
| Name | Insider Ownership | Earnings Growth |
| Shanghai Biren Technology (SEHK:6082) | 11% | 117.8% |
| Meitu (SEHK:1357) | 22.8% | 31.3% |
| Meiko Electronics (TSE:6787) | 19.2% | 30.1% |
| KebNi (OM:KEBNI B) | 11.8% | 105.2% |
| HUMAN MADE (TSE:456A) | 23.9% | 23.4% |
| Great Microwave Technology (SHSE:688270) | 29.5% | 85.5% |
| Gpixel Changchun Microelectronics (SEHK:3277) | 18.2% | 34.2% |
| Gold Road International (OB:GOLDR) | 35.9% | 86% |
| CD Projekt (WSE:CDR) | 35.2% | 39.6% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 14.1% | 41% |
We'll examine a selection from our screener results.
NextVision Stabilized Systems (TASE:NXSN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: NextVision Stabilized Systems, Ltd. develops, manufactures, and markets stabilized day and night cameras for ground and aerial vehicles in Israel and internationally with a market cap of ₪20.12 billion.
Operations: The company's revenue is primarily derived from its electronic security devices segment, which generated $250.65 million.
Insider Ownership: 21.8%
Return On Equity Forecast: N/A (2029 estimate)
NextVision Stabilized Systems is experiencing significant growth, with earnings expected to increase by 26.1% annually and revenue projected to grow at 27.3% per year, outpacing the IL market. Recent corporate guidance raised revenue targets for 2026 to US$355 million, reflecting a substantial increase over previous expectations. Despite high volatility in its share price, the company has reported strong financial results and secured multiple orders totaling millions of dollars, indicating robust demand for its products.
- Click to explore a detailed breakdown of our findings in NextVision Stabilized Systems' earnings growth report.
- Our comprehensive valuation report raises the possibility that NextVision Stabilized Systems is priced higher than what may be justified by its financials.
Voltronic Power Technology (TWSE:6409)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Voltronic Power Technology Corp., along with its subsidiaries, manufactures and sells uninterruptible power systems (UPS) in Taiwan and Mainland China, with a market cap of NT$90.33 billion.
Operations: The company's revenue primarily derives from the production and distribution of uninterruptible power systems (UPS) in Taiwan and Mainland China.
Insider Ownership: 21.1%
Return On Equity Forecast: 41% (2029 estimate)
Voltronic Power Technology faces challenges with a recent decline in net income and sales for the second quarter of 2026, reporting TWD 712.21 million in net income compared to TWD 1,496.02 million a year ago. Despite this, its earnings are forecasted to grow significantly at 27% per year, outpacing the TW market's growth rate. The company's return on equity is expected to be very high over the next three years, although its share price has been highly volatile recently.
- Delve into the full analysis future growth report here for a deeper understanding of Voltronic Power Technology.
- Our valuation report here indicates Voltronic Power Technology may be overvalued.
Caliway Biopharmaceuticals (TWSE:6919)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Caliway Biopharmaceuticals Co., Ltd. and its subsidiaries focus on developing drugs for aesthetic medicine and chronic inflammation, with a market cap of NT$159.43 billion.
Operations: The company generates revenue of NT$29.39 million from its pharmaceuticals segment, focusing on drug development for aesthetic medicine and chronic inflammation.
Insider Ownership: 24.4%
Return On Equity Forecast: N/A (2029 estimate)
Caliway Biopharmaceuticals demonstrates potential as a growth company with high insider ownership, despite reporting a net loss of TWD 222.52 million for Q2 2026 and declining sales. The company's innovative CBL-514 therapy, targeting systemic weight management by reducing fat cells, is advancing through significant clinical trials in collaboration with Eli Lilly's tirzepatide. With forecasts indicating rapid revenue growth at 126.3% annually and profitability within three years, Caliway remains an intriguing prospect amidst ongoing clinical developments.
- Unlock comprehensive insights into our analysis of Caliway Biopharmaceuticals stock in this growth report.
- Upon reviewing our latest valuation report, Caliway Biopharmaceuticals' share price might be too optimistic.
Taking Advantage
- Unlock our comprehensive list of 728 Fast Growing Global Companies With High Insider Ownership by clicking here.
- Ready For A Different Approach? Uncover 22 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com